Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury

Hepatology Research

Volumn 45, Issue 7, 2015, Pages 794-803

  Saiman, Yedidya ^a   Jiao, Jingjing ^a,b   Fiel, M Isabel ^a   Friedman, Scott L ^a   Aloman, Costica ^a,c   Bansal, Meena B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

CXCL12; CXCR4; Hepatic stellate cells; Liver fibrosis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INHIBITION KINETICS; LIVER INJURY; LIVER NECROSIS; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84935582020     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12411     Document Type: Article

References (35)

1. Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol 2012; 3: 213.
2. Seki E, De Minicis S, Gwak G etal. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119: 1858-1870.
3. Ajuebor MN, Hogaboam CM, Le T, Swain MG. C-C chemokine ligand 2/monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J Immunol 2003; 170: 5252-5259.
4. Seki E, de Minicis S, Inokuchi S etal. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50: 185-197.
5. Bonacchi A, Petrai I, Defranco RM etal. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003; 125: 1060-1076.
6. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009; 200: 1774-1780.
7. Zhang W, Fei Y, Gao J, Liu B, Zhang F. The role of CXCR3 in the induction of primary biliary cirrhosis. Clin Dev Immunol 2011; 2011: 564062.
8. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353: 104-108.
9. Harb R, Xie G, Lutzko C etal. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 2009; 137: 704-712.
10. Hashmi A, Hakim W, Kruglov E etal. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G395-401.
11. McCandless EE, Piccio L, Woerner BM etal. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol 2008; 172: 799-808.
12. Dotan I, Werner L, Vigodman S etal. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-592.
13. Dai S, Yuan F, Mu J etal. Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol 2010; 49: 587-597.
14. Jujo K, Hamada H, Iwakura A etal. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 11008-11013.
15. Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012; 52: 906-914.
16. Wald O, Pappo O, Safadi R etal. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disearse that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34: 1164-1174.
17. Hong F, Tuyama A, Lee T etal. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor 1a mediated stellate cell activation. Hepatology 2009; 49: 2055-2067.
18. Sawitza I, Kordes C, Reister S, Haussinger D. The niche of stellate cells within rat liver. Hepatology 2009; 50: 1617-1624.
19. Wintermeyer P, Cheng CW, Gehring S etal. Invariant natural killer T cells suppress the neutrophil inflammatory response in a mouse model of cholestatic liver damage. Gastroenterology 2009; 136: 1048-1059.
20. Novobrantseva TI, Majeau GR, Amatucci A etal. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005; 115: 3072-3082.
21. Karlmark KR, Weiskirchen R, Zimmermann HW etal. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50: 261-274.
22. Connolly MK, Bedrosian AS, Mallen-St Clair J etal. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119: 3213-3225.
23. Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol 2012; 28: 203-208.
24. Mark AL, Sun Z, Warren DS etal. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg 2010; 252: 591-596.
25. Broxmeyer HE, Orschell CM, Clapp DW etal. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318.
26. Stroncek DF, Clay ME, Herr G etal. The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfus Med 1997; 7: 19-24.
27. Zheng D, Oh SH, Jung Y, Petersen BE. Oval cell response in 2-acetylaminofluorene/partial hepatectomy rat is attenuated by short interfering RNA targeted to stromal cell-derived factor-1. Am J Pathol 2006; 169: 2066-2074.
28. Mavier P, Martin N, Couchie D, Preaux AM, Laperche Y, Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol 2004; 165: 1969-1977.
29. Tsuchiya A, Imai M, Kamimura H etal. Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice. Dig Dis Sci 2012; 57: 2892-2900.
30. Migliaccio AR, Martelli F, Verrucci M etal. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 2008; 36: 158-171.
31. De Clercq E, Yamamoto N, Pauwels R etal. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38: 668-674.
32. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009; 75: 1240-1247.
33. Martinez-Mier G, Toledo-Pereyra LH, McDuffie JE, Warner RL, Ward PA. Neutrophil depletion and chemokine response after liver ischemia and reperfusion. J Invest Surg 2001; 14: 99-107.
34. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997; 100: 279-289.
35. Devi S, Wang Y, Chew WK etal. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. J Exp Med 2013; 210: 2321-2336.